These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 33109026)
1. COVID-19 Vaccine Race: Analysis of Age-Dependent Immune Responses against SARS-CoV-2 Indicates that more than Just One Strategy May Be Needed. Jimenez M; Campillo NE; Canelles M Curr Med Chem; 2021; 28(20):3964-3979. PubMed ID: 33109026 [TBL] [Abstract][Full Text] [Related]
2. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frederiksen LSF; Zhang Y; Foged C; Thakur A Front Immunol; 2020; 11():1817. PubMed ID: 32793245 [TBL] [Abstract][Full Text] [Related]
3. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
5. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector]. Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356 [TBL] [Abstract][Full Text] [Related]
6. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Russell RL; Pelka P; Mark BL Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067 [TBL] [Abstract][Full Text] [Related]
7. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19). Bennet BM; Wolf J; Laureano R; Sellers RS Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660 [TBL] [Abstract][Full Text] [Related]
8. Human and novel coronavirus infections in children: a review. Rajapakse N; Dixit D Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199 [TBL] [Abstract][Full Text] [Related]
10. SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis). Ietto G Med Hypotheses; 2020 Aug; 141():109779. PubMed ID: 32387756 [TBL] [Abstract][Full Text] [Related]
11. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes. Jain N; Shankar U; Majee P; Kumar A Infect Genet Evol; 2021 Jan; 87():104648. PubMed ID: 33264668 [TBL] [Abstract][Full Text] [Related]
12. Drug Discovery Strategies for SARS-CoV-2. Shyr ZA; Gorshkov K; Chen CZ; Zheng W J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801 [TBL] [Abstract][Full Text] [Related]
13. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955 [TBL] [Abstract][Full Text] [Related]
14. Super-rapid race for saving lives by developing COVID-19 vaccines. Uttarilli A; Amalakanti S; Kommoju PR; Sharma S; Goyal P; Manjunath GK; Upadhayay V; Parveen A; Tandon R; Prasad KS; Dakal TC; Ben Shlomo I; Yousef M; Neerathilingam M; Kumar A J Integr Bioinform; 2021 Mar; 18(1):27-43. PubMed ID: 33761582 [TBL] [Abstract][Full Text] [Related]
15. COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus. Tavakol S; Alavijeh MS; Seifalian AM Curr Pharm Des; 2021; 27(13):1553-1563. PubMed ID: 33100195 [TBL] [Abstract][Full Text] [Related]
16. Targets and strategies for vaccine development against SARS-CoV-2. Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049 [TBL] [Abstract][Full Text] [Related]
17. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection. Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699 [TBL] [Abstract][Full Text] [Related]